CAS Number: 120066-54-8
Gadolinium chelate.The meglumine gadopentetate is excreted into breast milk in clinically non-significant (0.02% of the maternal dose) amount and there have been no problems in infants whose mothers had received this contrast medium. It has been used in the pediatric and neonatal age. The various contrast media that are gadolinium derivatives and used for explorations with Magnetic Resonance Imaging (MRI) are considered compatible with breastfeeding because they are quickly eliminated (elimination half-life of less than 2 hours). They undergo very little metabolic changes and are virtually non-absorbable orally. They are structurally very similar to each other. Some have been shown to have no or minimal excretion into the milk. Less than 0.04% of the dose given to the mother ends just going into the milk.Due to its low oral bioavailability, intestinal absorption should be less than 1% of the dose took by the infant.The maximum dose received by the infant is considered less than 0.0004% of the maternal dose, which is much less than the dose administered to a newborn infant who undergoes a MRI scan. Most Radiology Scientific Societies agree that after an MRI scan is not necessary to temporarily stop breastfeeding. Some authors recommend avoiding the use on lactating women of some Gadolinium contrast media that would pose a high risk for developing Systemic Nephrogenic Fibrosis, especially in the neonatal period, like gadoversetamide, and gadodiamide dimeglumine, by using instead low-risk ones like gadoterate, gadoteridol and gadobutrol.
CAS Number: 112188-16-6
There is no published experience with gadoteridol during breastfeeding. Guidelines developed by several professional organizations state that breastfeeding need not be disrupted after a nursing mother receives a gadolinium-containing contrast medium.[1][2][3] Gadoteridol is one of the most stable gadolinium agents, theoretically making it one of the safer drugs to use during breastfeeding. However, because there is no published experience with gadoteridol during breastfeeding, other agents may be preferred, especially while nursing a newborn or preterm infant.
As usage of Prohance | Gadoteridol Injection is mostly safe while breastfeeding hence there should not be any concern. In case of any change in behavior or health of your baby you should inform your health care provider about usage of Prohance | Gadoteridol Injection else no further action is required.
Definitely, Prohance | Gadoteridol Injection is safe in lactation for baby. No wonder your doctor has recommended it.
No extra baby monitoring required while mother is using Prohance | Gadoteridol Injection
US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday
UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700
Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week
Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week